Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: Results from a population-based study

Journal of Cancer Epidemiology

Volumn , Issue , 2012, Pages

  Vo, Thao T ^a   Nelson, Jeanenne J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR RISK; DATA BASE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEOPLASM; POPULATION RESEARCH; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 84861029997     PISSN: 16878558     EISSN: 16878566     Source Type: Journal    
DOI: 10.1155/2012/529357     Document Type: Article

References (25)

1. Ballatori E., Roila F., Ruggeri B., Betti M., Sarti S., Soru G., Cruciani G., Di Maio M., Andrea B., Deuson R. R., The impact of chemotherapy-induced nausea and vomiting on health-related quality of life Suppo (Pubitemid 46332920)
2. Navari R. M., Antiemetic control: toward a new standard of care for emetogenic chemotherapy Expert Opinion on Pharmacotherapy 2009 10 4 629 644
3. de Marco M. F., Janssen-Heijnen M. L. G., van der Heijden L. H., Coebergh J. W. W., Comorbidity and colorectal cancer according to subsite and stage; a population-based study European Journal of Cancer 2000 36 1 95 99 (Pubitemid 30035350)
4. Yancik R., Cancer burden in the aged: an epidemiologic and demographic overview Cancer 1997 80 7 1273 1283 (Pubitemid 27407230)
5. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., Barbera S., Ferrau F., Piazza E., Rosetti F., Clerici M., Bertetto O., Robbiati S. F., Frontini L., Sacco C., Castiglione F., Favaretto A., Novello S., Migliorino M. R., Gasparini G., Galetta D., Iaffaioli R. V., Gebbia V., Celano A., Schiavon S., Illiano A., Raucci C. A., Caruso M., Foa P., Tonini G., Curcio C., Cazzaniga M., Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial Journal of the National Cancer Institute 2003 95 5 362 372 (Pubitemid 36395256)
6. Keefe D. L., The cardiotoxic potential of the 5-HT 3 receptor antagonist antiemetics: is there cause for concern? Oncologist 2002 7 1 65 72 (Pubitemid 34151109)
7. Monsuez J. J., Charniot J. C., Vignat N., Artigou J. Y., Cardiac side-effects of cancer chemotherapy International Journal of Cardiology 2010 144 1 3 15
8. Yeh E. T., Bickford C. L., Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management Journal of the American College of Cardiology 2009 53 24 2231 2247
9. Pai V. B., Nahata M. C., Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention Drug Safety 2000 22 4 263 302 (Pubitemid 30213944)
10. Sankhala K. K., Pandya D. M., Sarantopoulos J., Soefje S. A., Giles F. J., Chawla S. P., Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant Expert Opinion on Drug Metabolism and Toxicology 2009 5 12 1607 1614
11. Ruhlmann C. H., Herrstedt J., Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting Expert Opinion on Drug Safety 2011 10 3 449 462
12. Merck Co. EMEND (aprepitant) capsules,. prescribing information, (GENERIC). Ref Type: Electronic Citation, 2011, http://www.merck.com/index.html
13. Warr D. G., Grunberg S. M., Gralla R. J., Hesketh P. J., Roila F., de Wit R., Carides A. D., Taylor A., Evans J. K., Horgan K. J., The oral NK 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials European Journal of Cancer 2005 41 9 1278 1285 (Pubitemid 40813003)
14. Hesketh P. J., Grunberg S. M., Gralla R. J., Warr D. G., Roila F., de Wit R., Chawla S. P., Carides A. D., Ianus J., Elmer M. E., Evans J. K., Beck K., Reines S., Horgan K. J., The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatinthe Aprepitant Protocol 052 Study Group Journal of Clinical Oncology 2003 21 22 4112 4119 (Pubitemid 46606178)
15. Poli-Bigelli S., Rodrigues-Pereira J., Carides A. D., Ma G. J., Eldridge K., Hipple A., Evans J. K., Horgan K. J., Lawson F., Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 2003 97 12 3090 3098 (Pubitemid 36676265)
16. Hesketh P. J., Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice Oncologist 1999 4 3 191 196 (Pubitemid 29297482)
17. Grunberg S. M., Osoba D., Hesketh P. J., Gralla R. J., Borjeson S., Rapoport B. L., Du Bois A., Tonato M., Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicityan update Supportive Care in Cancer 2005 13 2 80 84 (Pubitemid 40558162)
18. Lloyd-Jones D., Adams R. J., Brown T. M., Carnethon M., Dai S., de Simone G., Ferguson T. B., Ford E., Furie K., Gillespie C., Go A., Greenlund K., Haase N., Hailpern S., Ho P. M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M. M., Meigs J., Mozaffarian D., Mussolino M., Nichol G., Roger V. L., Rosamond W., Sacco R., Sorlie P., Stafford R., Thom T., Wasserthiel-Smoller S., Wong N. D., Wylie-Rosett J., Executive summary: heart disease and stroke statistics2010 update: a report from the american heart association Circulation 2010 121 7 e46 e215
19. Curran M. P., Robinson D. M., Aprepitant: a review of its use in the prevention of nausea and vomiting Drugs 2009 69 13 1853 1878
20. de Jonge M. E., Huitema A. D. R., Holtkamp M. J., van Dam S. M., Beijnen J. H., Rodenhuis S., Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism Cancer Chemotherapy and Pharmacology 2005 56 4 370 378 (Pubitemid 41095400)
21. Navari R. M., Koeller J. M., Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine 3 receptor antagonists Annals of Pharmacotherapy 2003 37 9 1276 1286 (Pubitemid 37040221)
22. Sorensen H. T., S. P. Johnsen, Norgard B., Methodological issues in using prescription and other databases in pharmacoepidemiology Norwegian Journal of Epidemiology 2001 11 1 13 18
23. Wahl P. M., Rodgers K., Schneeweiss S., Gage B. F., Butler J., Wilmer C., Nash M., Esper G., Gitlin N., Osborn N., Short L. J., Bohn R. L., Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population Pharmacoepidemiology and Drug Safety 2010 19 6 596 603
24. Aapro M. S., Optimising antiemetic therapy: what are the problems and how can they be overcome? Current Medical Research and Opinion 2005 21 6 885 897 (Pubitemid 40903079)
25. Schwartzberg L. S., Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology 2007 21 8 946 953 (Pubitemid 47106308)